Joseph A. Sparano, MD, on TAILORx: Influencing the Standard of Care for Women With Node-Negative, Hormone Receptor–Positive Breast Cancer

Posted: Thursday, January 5, 2023

Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses the ways in which findings from the TAILORx trial have changed the face of treatment for many patients with early-stage breast cancer, enabling them to forgo chemotherapy. He also details with extended follow-up, late relapses more than 5 years after diagnosis exceeded early relapse, and that racial disparities seen were among Black women who tended to experience a higher risk of early relapse within 5 years of diagnosis.